medigraphic.com
Colegio de Medicina Interna de México.

2023, Número 5

<< Anterior Siguiente >>

Med Int Mex 2023; 39 (5)


Tratamiento tópico vs sistémico para el alivio del dolor neuropático localizado

Nieto GW, Reymer D, Zapata C, Camacho G, Sotelo L, García J, Ortiz I

Idioma: Español
Referencias bibliográficas: 53
Paginas: 760-767
Archivo PDF: 261.85 Kb.


RESUMEN

Según la Asociación Internacional para el Estudio del Dolor, el dolor neuropático se define como el dolor producto de una lesión o enfermedad que afecta al sistema somatosensorial, donde se involucran mecanismos fisiopatológicos periféricos y centrales en las fibras nerviosas del dolor y en los canales iónicos. Si bien la caracterización topográfica de la lesión es necesaria al momento de determinar la elección del tratamiento de primera línea, la falta de consenso en la definición del dolor neuropático localizado y la escasa comprensión del término ha llevado a heterogeneidades en su descripción. El tratamiento del dolor neuropático localizado incluye terapias sistémicas y tópicas; sin embargo, debido a que este tipo de lesión está limitado a una zona reducida, se propone que los tratamientos localizados, como los tópicos, podrían ser los ideales debido a los menores efectos secundarios, interacciones con otros fármacos y la eficacia satisfactoria en el alivio del dolor. Este artículo discute las modalidades farmacológicas para el tratamiento del dolor neuropático y el dolor neuropático localizado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Treede RD, Jensen TS, Campbell JN, Cruccu G, DostrovskyJO, Griffin JW, et al. Neuropathic pain: redefinition anda grading system for clinical and research purposes.Neurology 2008; 70 (18): 1630-5. doi: 10.1212/01.wnl.0000282763.29778.59.

  2. Pickering G, Martin E, Tiberghien F, Delorme C, Mick G.Localized neuropathic pain: an expert consensus on localtreatments. Drug Des Devel Ther 2017; 11: 2709-18. doi:10.2147/DDDT.S142630.

  3. Casale R, Mattia C. Building a diagnostic algorithm on localizedneuropathic pain (LNP) and targeted topical treatment:focus on 5% lidocaine-medicated plaster. Ther Clin RiskManag 2014; 10: 259-68. doi: 10.2147/TCRM.S58844.

  4. Bennett M. The LANSS Pain Scale: the Leeds assessmentof neuropathic symptoms and signs. Pain 2001; 92 (1-2):147-57. doi: 10.1016/s0304-3959(00)00482-6.

  5. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSSscore for identifying pain of predominantly neuropathicorigin: validation for use in clinical and postal research. JPain 2005; 6 (3): 149-58. doi: 10.1016/j.jpain.2004.11.007.

  6. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis,pathophysiological mechanisms, and treatment.Lancet Neurol 2010; 9 (8): 807-19. doi: 10.1016/S1474-4422(10)70143-5.

  7. Fine PG. Chronic pain management in older adults: specialconsiderations. J Pain Symptom Manage 2009; 38 (2 Suppl):S4-s14. doi: 10.1016/j.jpainsymman.2009.05.002.

  8. Mick G, Baron R, Correa-Illanes G, Hans G, Mayoral V,Frías X, et al. Is an easy and reliable diagnosis of localizedneuropathic pain (LNP) possible in general practice?Development of a screening tool based on IASPcriteria. Curr Med Res Opin 2014; 30 (7): 1357-66. doi:10.1185/03007995.2014.907562.

  9. Mick G, Baron R, Finnerup NB, Hans G, Kern KU, Brett B, etal. What is localized neuropathic pain? A first proposal tocharacterize and define a widely used term. Pain Manag2012; 2 (1): 71-7. doi: 10.2217/pmt.11.77.

  10. Mayoral V, Pérez-Hernández C, Muro I, Leal A, Villoria J,Esquivias A. Diagnostic accuracy of an identification toolfor localized neuropathic pain based on the IASP criteria.Curr Med Res Opin 2018; 34 (8): 1465-73. https://doi.org/10.1080/03007995.2018.1465905.

  11. Casale R, Symeonidou Z, Bartolo M. Topical treatments forlocalized neuropathic pain. Current Pain and HeadacheReports 2017; 21 (3): 15. doi: 10.1007/s11916-017-0615-y.

  12. Zur E. Topical treatment of neuropathic pain using compoundedmedications. Clin J Pain 2014; 30 (1): 73-91. doi:10.1097/AJP.0b013e318285d1ba.

  13. Kalso E. The vicious circle in chronic pain management: balancingefficacy and adverse effects. Curr Med Res Opin 2011;27 (10): 2069-71. doi: 10.1185/03007995.2011.619436.

  14. Jorge LL, Feres CC, Teles VE. Topical preparations for painrelief: efficacy and patient adherence. J Pain Res 2010; 4:11-24. doi: 10.2147/JPR.S9492.

  15. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA,et al. Pharmacological management of chronic neuropathicpain: revised consensus statement from the CanadianPain Society. Pain Res Manag 2014; 19 (6): 328-35. doi:10.1155/2014/754693.

  16. International Association for the study of pain [Internet].USA: IASP; 2020 [citado 30 nov 2021] The NeuropathicPain SIG (NeuPSIG) will advance the understanding ofmechanisms, assessment, prevention, and treatment ofneuropathic pain [Available from: https://www.iasp-pain.org/group/neuropathic-pain-neupsig/.

  17. Acevedo JC, Amaya A, Casasola Ode L, Chinchilla N, DeGiorgis M, Florez S, et al. Guidelines for the diagnosis andmanagement of neuropathic pain: consensus of a group ofLatin American experts. J Pain Palliat Care Pharmacother2009; 23 (3): 261-81. doi: 10.1080/15360280903098572.

  18. Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH,Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers2017; 3: 17002. doi: 10.1038/nrdp.2017.2.

  19. Cavalli E, Mammana S, Nicoletti F, Bramanti P, MazzonE. The neuropathic pain: An overview of the currenttreatment and future therapeutic approaches. Int J ImmunopatholPharmacol 2019; 33: 2058738419838383.doi: 10.1177/2058738419838383.

  20. Taylor CP. The biology and pharmacology of calciumchannel alpha2-delta proteins Pfizer Satellite Symposiumto the 2003 Society for Neuroscience Meeting. SheratonNew Orleans Hotel, New Orleans, LA November 10, 2003.CNS Drug Rev 2004; 10 (2): 183-8. oi: 10.1111/j.1527-3458.2004.tb00012.x.

  21. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, MooreRA. Pregabalin for neuropathic pain in adults. CochraneDatabase Syst Rev 2019 (1). doi: 10.1002/14651858.CD007076.pub3.

  22. Wiffen PJ, Derry S, Bell RF, Rice ASC, Tölle TR, Phillips T, etal. Gabapentin for chronic neuropathic pain in adults. CochraneDatabase Syst Rev 2017 (6). doi: 10.1002/14651858.CD007938.pub4.

  23. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressantsin the treatment of neuropathic pain. Basic Clin PharmacolToxicol 2005; 96 (6): 399-409. doi: 10.1111/j.1742-7843.2005.pto_96696601.x.

  24. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain.Cochrane Database Syst Rev 2007; 4: CD005454. doi:10.1002/14651858.CD005454.pub2.

  25. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P,Iyengar S, et al. A randomized controlled trial of duloxetinein diabetic peripheral neuropathic pain. Neurology 2006; 67(8): 1411-20. doi: 10.1212/01.wnl.0000240225.04000.1a.

  26. An update on the drug treatment of neuropathic pain. Part1: antidepressants. Drug Ther Bull 2012; 50 (10): 114. doi:10.1136/dtb.2012.10.0133.

  27. Rincon Carvajal A, Olaya Osorio C, Martinez Rojas S, BernalI. Evidence-based recommendations for the managementof neuropathic pain (review of the literature). Rev Soc EspDolor 2018; 25 (6): 349-58.

  28. Sheets MF, Hanck DA. Molecular action of lidocaine on thevoltage sensors of sodium channels. J Gen Physiol 2003;121 (2): 163-75. doi: 10.1085/jgp.20028651.

  29. De León-Casasola OA, Mayoral V. The topical 5% lidocainemedicated plaster in localized neuropathic pain:a reappraisal of the clinical evidence. J Pain Res 2016;9: 67-79.

  30. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocainefor neuropathic pain in adults. Cochrane Database Syst Rev2014; 2014 (7): CD010958-CD. doi: 10.1002/14651858.CD010958.pub2.

  31. Buksnys T, Armstrong N, Worthy G, Sabatschus I, BoeslI, Buchheister B, et al. Systematic review and networkmeta-analysis of the efficacy and safety of lidocaine 700 mgmedicated plaster vs. pregabalin. Curr Med Res Opin 2020;36 (1): 101-15. doi: 10.1080/03007995.2019.1662687.

  32. Moisset X, Bouhassira D, Avez Couturier J, Alchaar H,Conradi S, Delmotte MH, et al. Pharmacological andnon-pharmacological treatments for neuropathic pain:Systematic review and French recommendations. RevNeurol (Paris) 2020; 176 (5): 325-52. doi: 10.1016/j.neurol.2020.01.361.

  33. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerabilityof the lidocaine patch 5%, a targeted peripheralanalgesic: a review of the literature. J Clin Pharmacol 2003;43 (2): 111-7. doi: 10.1177/0091270002239817.

  34. Delorme C, Navez ML, Legout V, Deleens R, Moyse D.Treatment of neuropathic pain with 5% lidocaine-medicatedplaster: Five years of clinical experience. Pain ResManag 2011; 16 (4): 259-63. doi: 10.1155/2011/359591.

  35. Galer BS, Gammaitoni AR. More than 7 years of consistentneuropathic pain relief in geriatric patients. Arch InternMed 2003; 163 (5): 628. doi: 10.1001/archinte.163.5.628.

  36. Anand P, Bley K. Topical capsaicin for pain management:therapeutic potential and mechanisms of action of the newhigh-concentration capsaicin 8% patch. Br J Anaesth 2011;107 (4): 490-502. doi: 10.1093/bja/aer260.

  37. Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN.Spontaneous pain, both neuropathic and inflammatory, isrelated to frequency of spontaneous firing in intact C-fibernociceptors. J Neurosci 2006; 26 (4): 1281-92. doi: 10.1523/JNEUROSCI.3388-05.2006.

  38. Kennedy WR. Opportunities afforded by the study of unmyelinatednerves in skin and other organs. Muscle Nerve2004; 29 (6): 756-67. doi: 10.1002/mus.20062.

  39. Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin(high concentration) for chronic neuropathic pain in adults.Cochrane Database Syst Rev 2017; 1 (1): Cd007393. doi:10.1002/14651858.CD007393.pub4.

  40. Sawynok J. Topical analgesics for neuropathic pain: preclinicalexploration, clinical validation, future development.Eur J Pain 2014; 18 (4): 465-81. doi: 10.1002/j.1532-2149.2013.00400.x.

  41. Anitescu M, Benzon HT, Argoff CE. Advances in topicalanalgesics. Curr Opin Anaesthesiol 2013; 26 (5): 555-61.doi: 10.1097/01.aco.0000432514.00446.22.

  42. Bajaj S, Whiteman A, Brandner B. Transdermal drugdelivery in pain management. Continuing education inanaesthesia. Crit Care Pain 2011; 11 (2): 39-43. https://doi.org/10.1093/bjaceaccp/mkq054.

  43. Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptylineand ketamine in neuropathic pain syndromes: anopen-label study. J Pain 2005; 6 (10): 644-9. doi: 10.1016/j.jpain.2005.04.008.

  44. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topicalamitriptyline versus lidocaine in the treatment of neuropathicpain. Clin J Pain 2008; 24 (1): 51-5. doi: 10.1097/AJP.0b013e318156db26.

  45. Allegri M, Baron R, Hans G, Correa-Illanes G, Mayoral RojalsV, Mick G, et al. A pharmacological treatment algorithmfor localized neuropathic pain. Curr Med Res Opin 2016;32 (2): 377-84. doi: 10.1185/03007995.2015.1129321.

  46. ClinicalTrials.gov. USA: Clinical Trials; 2017. Localized neuropathicpain: Topical treatment versus systemic treatment(PELICAN). Available from: https://clinicaltrials.gov/ct2/show/NCT03348735.

  47. Pickering G, Lucchini C. Topical treatment of localizedneuropathic pain in the elderly. Drugs Aging 2020; 37 (2):83-9. doi: 10.1007/s40266-019-00739-9.

  48. Clère F, Delorme-Morin C, George B, Navez M, Rioult B,Tiberghien-Chatelain F, et al. 5% lidocaine medicated plasterin elderly patients with postherpetic neuralgia: results of acompassionate use programme in France. Drugs Aging 2011;28 (9): 693-702. doi: 10.2165/11595600-000000000-00000.

  49. Barkin RL. The pharmacology of topical analgesics. PostgradMed 2013; 125 (4 Suppl 1): 7-18. doi: 10.1080/00325481.2013.1110566911.

  50. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderlypatients. Am J Geriatr Pharmacother 2007; 5 (4): 345-51.doi: 10.1016/j.amjopharm.2007.12.002.

  51. Pickering G, Voute M, Macian N, Ganry H, Pereira B. Effectivenessand safety of 5% lidocaine-medicated plaster on localizedneuropathic pain after knee surgery: a randomized,double-blind controlled trial. Pain 2019; 160 (5): 1186-95.doi: 10.1097/j.pain.0000000000001502.

  52. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R,Dworkin RH, et al. Pharmacotherapy for neuropathic pain inadults: a systematic review and meta-analysis. Lancet Neurol2015; 14 (2): 162-73. doi: 10.1016/S1474-4422(14)70251-0.

  53. US Department of Health and Human Services. Pain managmentbest practice inter-agency task force report. In:Health and Human Services, editor. USA: US Departmentof Health and Human Services; 2019.




2020     |     www.medigraphic.com